Hemab Therapeutics Holdings, Inc. (COAG)
| Market Cap | 1.51B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -71.29M |
| Shares Out | 46.71M |
| EPS (ttm) | -75.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 329,158 |
| Open | 27.56 |
| Previous Close | 27.72 |
| Day's Range | 27.56 - 33.18 |
| 52-Week Range | 23.00 - 36.61 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 41.40 (+27.9%) |
| Earnings Date | Aug 5, 2026 |
About COAG
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovale... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for COAG stock is "Strong Buy." The 12-month stock price target is $41.4, which is an increase of 27.90% from the latest price.
News
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous dosing;...
Hemab Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Hemab Therapeutics (COAG) with a Buy rating and $40 price target Hemab is a mid-stage biotech building “first-in-class” antibody franchises with subcutaneous prop...
Hemab Therapeutics Holdings Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing a pipeline of therapies for rare bleeding disorders, with its lead asset entering phase III and additional programs progressing in Factor VII deficiency and von Willebrand disease. Strong efficacy, regulatory alignment, and a robust financial position support global development plans.
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment o...
Hemab Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI initiated coverage of Hemab Therapeutics (COAG) with an Outperform rating and $50 price target citing the combination of significant unmet need, limited competition and multiple upcoming ...
Wedbush bullish on Hemab Therapeutics, initiates with an Outperform
As previously reported, Wedbush analyst David Nierengarten initiated coverage of Hemab Therapeutics (COAG) with an Outperform rating and $42 price target The firm views Hemab Therapeutics as a high co...
Hemab Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten initiated coverage of Hemab Therapeutics (COAG) with an Outperform rating and $42 price target
Hemab Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft initiated coverage of Hemab Therapeutics (COAG) with a Buy rating and $39 price target The company is positioned transform care in rare bleeding disorders, similar to…
Hemab Therapeutics initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Hemab Therapeutics (COAG) with a Buy rating and $36 price target The company has multiple assets in development to treat orphan and large bleeding disorders,…
Hemab Therapeutics Holdings Earnings release: Q1 2026
Hemab Therapeutics Holdings released its Q1 2026 earnings on May 21, 2026, summarizing the period's financial results.
Hemab Therapeutics Holdings Quarterly report: Q1 2026
Hemab Therapeutics Holdings has published its Q1 2026 quarterly earnings report on May 21, 2026.
Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine ...
Hemab Therapeutics opens at $27, IPO priced at $18 per share
Hemab Therapeutics (COAG) priced 16.75M shares at $18.00. The deal size was increased to 16.75M shares from 15.0M and priced at the top end of the $16.00-$18.00 target range. Goldman…
Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagin...
Hemab Therapeutics Holdings IPO Registration Document (S-1)
Hemab Therapeutics Holdings has filed to go public with an IPO on the NASDAQ